Page last updated: 2024-12-10
plumericin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
plumericin: from bark of Plumeria rubra; structure given in first source; RN given refers to (3aS-(3E,3aalpha,4abeta,7abeta,9aR*,9bbeta))-isomer; RN for cpd without isomeric designation not avail 5/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Plumeria | genus | A plant genus of the family APOCYNACEAE that contains plumericin, uleine and demethoxyaspidospermine.[MeSH] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5281545 |
CHEMBL ID | 517300 |
CHEBI ID | 8274 |
SCHEMBL ID | 4894690 |
MeSH ID | M0187355 |
Synonyms (24)
Synonym |
---|
plumericin |
2h,4,5-trioxadicyclopent[a,hi]indene-7-carboxylic acid, 3-ethylidene-3,3a,7a,9b-tetrahydro-2-oxo-, methyl ester, [3as-(3e,3a.alpha.,4a.beta.,7a.beta.,9ar*,9b.beta.)]- |
77-16-7 |
2h,4,5-trioxa-1h-dicyclopent[a,hi]indene-7-carboxylic acid, 3-ethylidene-3,3a.beta.,7a.alpha.,9b.alpha.-tetrahydro-2-oxo-, methyl ester |
nsc-112152 |
methyl (e)-ethylidene(oxo)[?]carboxylate |
C09796 |
chebi:8274 , |
plurnericin |
CHEMBL517300 |
nsc 112152 |
2h,4ah-1,4,5-trioxadicyclopent(a,hi)indene-7-carboxylic acid, 3-ethylidene-3,3a,7a,9b-tetrahydro-2-oxo-, methyl ester, (3e,3as,4ar,7as,9as,9bs)- |
l0126u506z , |
2h,4ah-1,4,5-trioxadicyclopent(a,hi)indene-7-carboxylic acid, 3-ethylidene-3,3a,7a,9b-tetrahydro-2-oxo-, methyl ester, (3as-(3e,3aalpha,4abeta,7abeta,9ar*,9bbeta))- |
unii-l0126u506z |
nci-112152 |
(1r,5s,8s,9s,10s)-plumericin |
plumericin [mi] |
(+)-plumericin |
SCHEMBL4894690 |
bdbm50480284 |
Q27108026 |
DTXSID301018956 |
methyl (1s,4s,8r,10s,11e,14s)-11-ethylidene-12-oxo-7,9,13-trioxatetracyclo[6.5.1.01,10.04,14]tetradeca-2,5-diene-5-carboxylate |
Research Excerpts
Overview
Plumericin is a potent inhibitor of NF-κB pathways with a new chemical scaffold.
Excerpt | Reference | Relevance |
---|---|---|
"Plumericin is a potent inhibitor of NF-κB pathways with a new chemical scaffold. " | ( Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivo. Atanasov, AG; Awad, EM; Bochkov, V; Breuss, JM; Cabaravdic, M; Dirsch, VM; Fakhrudin, N; Grzywacz, AM; Heiss, EH; Liu, R; Malainer, C; Mihaly-Bison, J; Noha, SM; Rollinger, JM; Schachner, D; Schuster, D; Stuppner, H; Waltenberger, B, 2014) | 2.18 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
terpene lactone | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (24)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID421907 | Cytotoxicity against human H460 cells | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID421910 | Cytotoxicity against human MCF7 cells | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID1514104 | Antileishmanial activity against Leishmania donovani amastigotes infected in mouse J774G8 cells after 48 to 72 hrs by Giemsa staining-based bright-field microscopic analysis | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Leishmania treatment and prevention: Natural and synthesized drugs. |
AID334065 | Cytotoxicity against mouse M109 cells | 1997 | Journal of natural products, Dec, Volume: 60, Issue:12 | Bioactive iridoids and a new lignan from Allamanda cathartica and Himatanthus fallax from the Suriname rainforest. |
AID1514103 | Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Leishmania treatment and prevention: Natural and synthesized drugs. |
AID336526 | Cytotoxicity against human lung cancer cells | |||
AID336528 | Cytotoxicity against human KB cells | |||
AID421906 | Cytotoxicity against mouse 3T3 cells | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID336523 | Cytotoxicity against human HT1080 cells | |||
AID338971 | Cytotoxicity against human 9KB cells | |||
AID421909 | Cytotoxicity against human DU145 cells | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID421908 | Cytotoxicity against human ME180 cells | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID336527 | Cytotoxicity against human colon cancer cells | |||
AID421918 | Antituberculosis activity against Mycobacterium tuberculosis H37Rv | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID338725 | Toxicity in brine shrimp | |||
AID338973 | Antitumor activity against Agrobacterium tumefaciens-induced crown gall tumor in potato tubers by potato disk assay | |||
AID421905 | Antimicrobial activity against Saccharomyces cerevisiae RS321 | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID421916 | Antileishmanial activity against Leishmania amazonensis axenic amastigotes | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID421912 | Cytotoxicity against human HT-29 cells | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A multipronged approach to the study of peruvian ethnomedicinal plants: a legacy of the ICBG-Peru Project. |
AID334066 | Antimicrobial activity against yeast Sc7 | 1997 | Journal of natural products, Dec, Volume: 60, Issue:12 | Bioactive iridoids and a new lignan from Allamanda cathartica and Himatanthus fallax from the Suriname rainforest. |
AID336524 | Cytotoxicity against human melanoma cells | |||
AID336525 | Cytotoxicity against human breast cancer cells | |||
AID397122 | Inhibition of HIV1 RT | |||
AID336529 | Cytotoxicity against mouse P388 cells | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (6.25) | 18.7374 |
1990's | 2 (12.50) | 18.2507 |
2000's | 6 (37.50) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 1 (6.25) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 23.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.59) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (15.79%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (84.21%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |